# Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

> **NCT05629208** · PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 20 (actual)

## Conditions studied

- Cutaneous Lupus Erythematosus (CLE)

## Interventions

- **DRUG:** Edecesertib
- **DRUG:** Edecesertib Placebo

## Key facts

- **NCT ID:** NCT05629208
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-04-17
- **Primary completion:** 2025-12-17
- **Final completion:** 2026-01-14
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05629208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05629208, "Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05629208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*